1. Home
  2. ERAS vs UXIN Comparison

ERAS vs UXIN Comparison

Compare ERAS & UXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • UXIN
  • Stock Information
  • Founded
  • ERAS 2018
  • UXIN 2011
  • Country
  • ERAS United States
  • UXIN China
  • Employees
  • ERAS N/A
  • UXIN N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • UXIN Business Services
  • Sector
  • ERAS Health Care
  • UXIN Consumer Discretionary
  • Exchange
  • ERAS Nasdaq
  • UXIN Nasdaq
  • Market Cap
  • ERAS 719.0M
  • UXIN 744.3M
  • IPO Year
  • ERAS 2021
  • UXIN 2018
  • Fundamental
  • Price
  • ERAS $2.67
  • UXIN $4.52
  • Analyst Decision
  • ERAS Strong Buy
  • UXIN
  • Analyst Count
  • ERAS 5
  • UXIN 0
  • Target Price
  • ERAS $6.10
  • UXIN N/A
  • AVG Volume (30 Days)
  • ERAS 1.7M
  • UXIN 194.6K
  • Earning Date
  • ERAS 11-12-2024
  • UXIN 11-26-2024
  • Dividend Yield
  • ERAS N/A
  • UXIN N/A
  • EPS Growth
  • ERAS N/A
  • UXIN N/A
  • EPS
  • ERAS N/A
  • UXIN N/A
  • Revenue
  • ERAS N/A
  • UXIN $204,611,457.00
  • Revenue This Year
  • ERAS N/A
  • UXIN $26.86
  • Revenue Next Year
  • ERAS N/A
  • UXIN N/A
  • P/E Ratio
  • ERAS N/A
  • UXIN N/A
  • Revenue Growth
  • ERAS N/A
  • UXIN N/A
  • 52 Week Low
  • ERAS $1.51
  • UXIN $1.41
  • 52 Week High
  • ERAS $3.45
  • UXIN $12.10
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 43.56
  • UXIN 50.77
  • Support Level
  • ERAS $2.59
  • UXIN $4.18
  • Resistance Level
  • ERAS $3.19
  • UXIN $5.00
  • Average True Range (ATR)
  • ERAS 0.20
  • UXIN 0.56
  • MACD
  • ERAS -0.02
  • UXIN -0.01
  • Stochastic Oscillator
  • ERAS 20.13
  • UXIN 54.73

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About UXIN Uxin Limited ADS

Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.

Share on Social Networks: